PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

Anna Maria Jegg, Toby M. Ward, Elizabeth Iorns, Nicholas Hoe, Jinyao Zhou, Xiaofei Liu, Sharat Singh, Ralf Landgraf, Mark D. Pegram

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved clinical outcome for women with ERBB2-amplified breast cancer. However, acquired resistance to lapatinib remains a significant clinical problem, and the mechanisms governing resistance remain poorly understood. We sought to define molecular alterations that confer an acquired lapatinib resistance phenotype in ER-/ERBB2+ human breast cancer cells. ERBB2-amplified SKBR3 breast cancer cells were rendered resistant to lapatinib via culture in increasing concentrations of the drug, and molecular changes associated with a resistant phenotype were interrogated using a collaborative enzyme-enhanced immunoassay platform and immunoblotting techniques for detection of phosphorylated signaling cascade proteins. Interestingly, despite apparent inactivation of the PI3K/AKT signaling pathway, resistant cells exhibited constitutive activation of mammalian target of rapamycin complex 1 (mTORC1) and were highly sensitive to mTOR inhibition with rapamycin and the dual PI3K/mTOR inhibitor NVP-BEZ235. These data demonstrate a role for downstream activation of mTORC1 in the absence of molecular alterations leading to PI3K/AKT hyperactivation as a potential mechanism of lapatinib resistance in this model of ERBB2+ breast cancer and support the rationale of combination or sequential therapy using ERBB2 and mTOR-targeting molecules to prevent or target resistance to lapatinib. Moreover, our data suggest that assessment of mTOR substrate phosphorylation (i.e., S6) may serve as a more robust biomarker to predict sensitivity to mTOR inhibitors in the context of lapatinib resistance than PI3K mutations, loss of PTEN and p-AKT levels.

Original languageEnglish
Pages (from-to)683-692
Number of pages10
JournalBreast Cancer Research and Treatment
Volume136
Issue number3
DOIs
StatePublished - Dec 1 2012

Fingerprint

Phosphatidylinositol 3-Kinases
Breast Neoplasms
Phenotype
S 6
mechanistic target of rapamycin complex 1
lapatinib
Sirolimus
Immunoenzyme Techniques
Immunoblotting
Phosphotransferases
Biomarkers
Phosphorylation
Mutation
Therapeutics
Pharmaceutical Preparations
Proteins

Keywords

  • Breast cancer
  • Clinical drug resistance
  • ERBB2-targeted therapy
  • Lapatinib
  • mTOR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. / Jegg, Anna Maria; Ward, Toby M.; Iorns, Elizabeth; Hoe, Nicholas; Zhou, Jinyao; Liu, Xiaofei; Singh, Sharat; Landgraf, Ralf; Pegram, Mark D.

In: Breast Cancer Research and Treatment, Vol. 136, No. 3, 01.12.2012, p. 683-692.

Research output: Contribution to journalArticle

Jegg, Anna Maria ; Ward, Toby M. ; Iorns, Elizabeth ; Hoe, Nicholas ; Zhou, Jinyao ; Liu, Xiaofei ; Singh, Sharat ; Landgraf, Ralf ; Pegram, Mark D. / PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. In: Breast Cancer Research and Treatment. 2012 ; Vol. 136, No. 3. pp. 683-692.
@article{d9d58f33ad97456ea3cbdda070a41ce5,
title = "PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells",
abstract = "Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved clinical outcome for women with ERBB2-amplified breast cancer. However, acquired resistance to lapatinib remains a significant clinical problem, and the mechanisms governing resistance remain poorly understood. We sought to define molecular alterations that confer an acquired lapatinib resistance phenotype in ER-/ERBB2+ human breast cancer cells. ERBB2-amplified SKBR3 breast cancer cells were rendered resistant to lapatinib via culture in increasing concentrations of the drug, and molecular changes associated with a resistant phenotype were interrogated using a collaborative enzyme-enhanced immunoassay platform and immunoblotting techniques for detection of phosphorylated signaling cascade proteins. Interestingly, despite apparent inactivation of the PI3K/AKT signaling pathway, resistant cells exhibited constitutive activation of mammalian target of rapamycin complex 1 (mTORC1) and were highly sensitive to mTOR inhibition with rapamycin and the dual PI3K/mTOR inhibitor NVP-BEZ235. These data demonstrate a role for downstream activation of mTORC1 in the absence of molecular alterations leading to PI3K/AKT hyperactivation as a potential mechanism of lapatinib resistance in this model of ERBB2+ breast cancer and support the rationale of combination or sequential therapy using ERBB2 and mTOR-targeting molecules to prevent or target resistance to lapatinib. Moreover, our data suggest that assessment of mTOR substrate phosphorylation (i.e., S6) may serve as a more robust biomarker to predict sensitivity to mTOR inhibitors in the context of lapatinib resistance than PI3K mutations, loss of PTEN and p-AKT levels.",
keywords = "Breast cancer, Clinical drug resistance, ERBB2-targeted therapy, Lapatinib, mTOR",
author = "Jegg, {Anna Maria} and Ward, {Toby M.} and Elizabeth Iorns and Nicholas Hoe and Jinyao Zhou and Xiaofei Liu and Sharat Singh and Ralf Landgraf and Pegram, {Mark D.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1007/s10549-012-2252-9",
language = "English",
volume = "136",
pages = "683--692",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

AU - Jegg, Anna Maria

AU - Ward, Toby M.

AU - Iorns, Elizabeth

AU - Hoe, Nicholas

AU - Zhou, Jinyao

AU - Liu, Xiaofei

AU - Singh, Sharat

AU - Landgraf, Ralf

AU - Pegram, Mark D.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved clinical outcome for women with ERBB2-amplified breast cancer. However, acquired resistance to lapatinib remains a significant clinical problem, and the mechanisms governing resistance remain poorly understood. We sought to define molecular alterations that confer an acquired lapatinib resistance phenotype in ER-/ERBB2+ human breast cancer cells. ERBB2-amplified SKBR3 breast cancer cells were rendered resistant to lapatinib via culture in increasing concentrations of the drug, and molecular changes associated with a resistant phenotype were interrogated using a collaborative enzyme-enhanced immunoassay platform and immunoblotting techniques for detection of phosphorylated signaling cascade proteins. Interestingly, despite apparent inactivation of the PI3K/AKT signaling pathway, resistant cells exhibited constitutive activation of mammalian target of rapamycin complex 1 (mTORC1) and were highly sensitive to mTOR inhibition with rapamycin and the dual PI3K/mTOR inhibitor NVP-BEZ235. These data demonstrate a role for downstream activation of mTORC1 in the absence of molecular alterations leading to PI3K/AKT hyperactivation as a potential mechanism of lapatinib resistance in this model of ERBB2+ breast cancer and support the rationale of combination or sequential therapy using ERBB2 and mTOR-targeting molecules to prevent or target resistance to lapatinib. Moreover, our data suggest that assessment of mTOR substrate phosphorylation (i.e., S6) may serve as a more robust biomarker to predict sensitivity to mTOR inhibitors in the context of lapatinib resistance than PI3K mutations, loss of PTEN and p-AKT levels.

AB - Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved clinical outcome for women with ERBB2-amplified breast cancer. However, acquired resistance to lapatinib remains a significant clinical problem, and the mechanisms governing resistance remain poorly understood. We sought to define molecular alterations that confer an acquired lapatinib resistance phenotype in ER-/ERBB2+ human breast cancer cells. ERBB2-amplified SKBR3 breast cancer cells were rendered resistant to lapatinib via culture in increasing concentrations of the drug, and molecular changes associated with a resistant phenotype were interrogated using a collaborative enzyme-enhanced immunoassay platform and immunoblotting techniques for detection of phosphorylated signaling cascade proteins. Interestingly, despite apparent inactivation of the PI3K/AKT signaling pathway, resistant cells exhibited constitutive activation of mammalian target of rapamycin complex 1 (mTORC1) and were highly sensitive to mTOR inhibition with rapamycin and the dual PI3K/mTOR inhibitor NVP-BEZ235. These data demonstrate a role for downstream activation of mTORC1 in the absence of molecular alterations leading to PI3K/AKT hyperactivation as a potential mechanism of lapatinib resistance in this model of ERBB2+ breast cancer and support the rationale of combination or sequential therapy using ERBB2 and mTOR-targeting molecules to prevent or target resistance to lapatinib. Moreover, our data suggest that assessment of mTOR substrate phosphorylation (i.e., S6) may serve as a more robust biomarker to predict sensitivity to mTOR inhibitors in the context of lapatinib resistance than PI3K mutations, loss of PTEN and p-AKT levels.

KW - Breast cancer

KW - Clinical drug resistance

KW - ERBB2-targeted therapy

KW - Lapatinib

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=84878770155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878770155&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2252-9

DO - 10.1007/s10549-012-2252-9

M3 - Article

C2 - 23089982

AN - SCOPUS:84878770155

VL - 136

SP - 683

EP - 692

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -